Continuous Glucose Monitor 'Dexcom G6'
90,000 KRW Monthly Cost with National Health Insurance Coverage
Huons announced on the 1st that it has decided to provide the continuous glucose monitor (CGM) 'Dexcom G6' transmitter free of charge to patients with type 1 diabetes.
Huons explained that this decision was made to reduce the medical expenses burden on patients with type 1 diabetes amid the recent economic downturn caused by rising prices. Accordingly, the Dexcom G6 transmitter (3-month supply) will be provided free of charge, changing from the previous price of 210,000 KRW. One pack of sensors (30-day supply) remains the same as before.
With the free transmitter support, patients with type 1 diabetes who receive health insurance benefits only need to pay 90,000 KRW for one month of use. Compared to before, this means they can purchase the Dexcom G6 at a 19% reduced cost. Among patients with type 1 diabetes, those eligible for medical aid (Type 1 and Type 2) and low-income groups can receive full reimbursement benefits, allowing them to use the Dexcom G6 without any out-of-pocket expenses as long as they have a prescription.
Huons expects that this decision will greatly improve accessibility and convenience for patients with type 1 diabetes who need to use continuous glucose monitors due to frequent blood sugar fluctuations. The Dexcom G6 automatically measures blood glucose every 5 minutes (up to 288 times a day) for 10 days with a single application and transmits the data to smart devices such as smartphones.
In addition to sending warning alarms in advance when rapid blood sugar changes are predicted, it automatically measures blood glucose levels even during times when self-monitoring is not possible, such as during sleep or exercise. Furthermore, blood glucose data can be shared with up to 10 people, including the patient’s family. Users can check not only glucose concentration but also trends and variability.
A Huons representative stated, "We decided to provide the Dexcom G6 transmitter free of charge to ease the burden on patients with type 1 diabetes. We hope this decision will improve access to diabetes management and enhance the quality of life for patients with type 1 diabetes. We will continue to do our best to support those struggling with diabetes."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
